According to news releases, the Canadian branch of Lupin Pharmaceuticals, the distributor of Rifaximin, recently announced that Health Canada, the Canadian drug regulatory agency, has approved its use for irritable bowel syndrome with diarrhea (IBS-D). Rifaximin, which is manufactured by Salix Pharmaceuticals in the United States, is known by the brand name Xifaxan in the U.S and as Zaxine in Canada. It is already available in Canada for use in other conditions and has been available in the U.S.for IBS-D since 2015.
Limited public information is available at this time. A link to the media release is provided below. IBS Impact will update as further reputable information becomes available.
Posted: December 2018